Krystal Biotech, Inc. (KRYS) Financials
KRYS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 1.4 billion | 120.2 million |
| Dec. 31, 2025 | 1.3 billion | 114.2 million |
| Sept. 30, 2025 | 1.2 billion | 102.2 million |
| June 30, 2025 | 1.1 billion | 97.7 million |
KRYS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | 73.2 million | 13.6 million |
| Dec. 31, 2025 | 75.4 million | 13.8 million |
| Sept. 30, 2025 | 38.0 million | 13.2 million |
| June 30, 2025 | 50.8 million | 14.1 million |
KRYS Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| March 31, 2026 | 55.9 million |
| Dec. 31, 2025 | 51.4 million |
| Sept. 30, 2025 | 79.4 million |
| June 30, 2025 | 38.3 million |
KRYS Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 823.4 million | - | 9.1 million |
| Dec. 31, 2025 | 827.8 million | - | 9.3 million |
| Sept. 30, 2025 | 731.1 million | - | 9.5 million |
| June 30, 2025 | 682.0 million | - | 9.7 million |
KRYS Shares Outstanding
KRYS Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 7.1 million | 15.3 million | 41.0 million | - |
| Dec. 31, 2025 | 2.1 million | 16.2 million | 41.3 million | - |
| Sept. 30, 2025 | 1.7 million | 13.2 million | 37.6 million | - |
| June 30, 2025 | 1.9 million | 14.4 million | 35.2 million | - |
KRYS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | 116.4 million | 6.3 million |
| Dec. 31, 2025 | 107.1 million | 10.9 million |
| Sept. 30, 2025 | 97.8 million | 5.7 million |
| June 30, 2025 | 96.0 million | 7.2 million |
KRYS
Price: $323.43
52 week price:
Earnings Per Share: 7.46 USD
P/E Ratio: 40.98
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 151900
Ebitda: -2.1 millionMarket Capitalization: 8.9 billion